Leadership

The importance of equitable approaches to diagnosis and treatment.

With lessons and perspectives from the field, the importance of harnessing the right combination of skills to advance up and across career ladders is explored.

Hill shares her insights on what is needed for a turnaround in talent development.

New C-Suite position emerges for more emphasis on patient centricity.

With an increase in drug development, why purpose should be the pharma industry’s secret advantage in the global talent shortage, as the COVID-19 crisis transitions into the endemic stage.

Reshma Kewalramani, MD, FASN, chief executive officer and president of Vertex Pharmaceuticals talks about how she supports the efforts of DE&I within and outside her organization.

Robert McMahon, former president of Merck US Human Health, shares some of the challenges leaders face when grappling with how to transform their organizations to embrace DE&I.

Benchmark study across healthcare sectors measures progress in advancing women and people of color into top leadership roles.

Why their influence on employee representation matters for pharma.

It takes flexibility and adaptability to switch a company’s focus. Here, Alkermes’ Chief Operating Officer Blair Jackson discusses how his team pivoted from developing CNS to oncology therapies and the skills it required.

Brennan describes what her career journey in pharma has looked like as a woman, and what she feels can be done to improve opportunities for other females in pharma. She also talks about how advocacy and commitment can similarly be applied to improve the rare disease space.

Mazur talks about his commitment to drug development and what it takes to succeed in the industry today.

For pharma teams, reaping the talent benefits requires skillful oversight.

In this installment of the Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A series, Michael Wong talks to Robert E. Siegel, lecturer in management at the Stanford Graduate School of Business, about determining the optimal combination of digital and physical assets for an S&P 500’s growth playbook.

Addressing whole employee is as important as treating whole patient.

Questions grow over adding titles to the biopharma C-suite.

It’s time to see how you’re doing with putting words into action.

Alicia H. Munnell, Peter F. Drucker Professor of Management Sciences at Boston College’s Carroll School of Management, talks about building long-term financial health via career sustainability.

Building and maintaining relationships can lead to better decisions.

Carolynn Johnson talks about changing the diversity, equity and includsion trends among the most progressive companies.

How can large pharma improve D&I in its companies?

Soft skills are needed to round out the hard numbers.

Examining the incumbent and imminent workforce.

If not addressed, effects could impact innovation, diversity.

Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.